TORONTO – A New Delta Subvariant COVID-19 Strain Has Been Named “version under investigation“By the UK, preliminary evidence suggests it may be more permeable than the delta.

- Advertisement -

The UK Health Protection Agency (UKHSA) said in an announcement published on Friday that the strain does not result in more severe disease or make vaccines less effective. It was also given the official name of “VUI-21OCT-01”.

The subvariant, formerly called “Delta Plus” or “AY.4.2”, was first detected in England in July. UKHSA’s data shows approximate 6 percent Recent COVID-19 cases in the UK, where case numbers are increasing, belong to this delta subvariant.

advertisement

UKHSA chief executive Dr. Jenny Harris said: “Viruses mutate frequently and randomly, and it is not unexpected that new variants will continue to arise as the pandemic progresses, especially when case rates remain high.” “It should serve as objective proof that this pandemic is not over.”

More investigation is needed to confirm whether the strain, which has also been found in Canada and weThe UKHSA says it’s actually more contagious than the delta version.

- Advertisement -

“As AY.4.2 is still at a fairly low frequency, a 10 per cent increase in its transmission efficiency may only lead to a few additional cases,” said François Balloux, director of the Institute of Genetics at University College London. Science Media Center on Tuesday. “As if it is not increasing the number of cases in the UK recently”

If the subvariant is indeed more permeable, Balloux said the difference would not be the same as that brought on by the delta variant, which was much more contagious than any strain in circulation at the time.

“We are dealing with a potentially small increase in transmission that will not have a comparable impact on the pandemic,” he said.

Very few cases of the new strain have been reported in Canada, but it is not clear if it is more contagious than the delta version, Dr. Angela Rasmussen, a virologist at the Vaccines and Infectious Diseases Organization at the University of Saskatchewan.

Dr. Rasmussen said the UK’s robust genomic surveillance, which they have at around 10 per cent of positive COVID-19 cases, may be one reason they have detected more cases.

“In many places, we still don’t have the surveillance capability to find these types,” he told Granthshala news channel on Wednesday. “They may not even be emerging. We haven’t really seen anything that indicates it’s becoming prevalent in Canada.”

Dr. Rasmussen also believes that it is likely that vaccines currently deployed in Canada will be effective against the subvariant.

“The vaccines we currently have are quite effective against the original prescription delta,” she said. “Of course, we should wait and see, we should see it, but there’s really nothing that stands out to me as a concern as to vaccine effectiveness against this particular sub-class.”